PCBP2 and pancreatic neoplasm: Moreover, the CCP/PCBP2 siRNA nanocomplex does not induce cytotoxicity in PANC-1 tumor cells and NIH 3T3 fibroblasts (Figure 6H-I), suggesting that the CCP/PCBP2 siRNA nanocomplex possesses a considerable potential to improve the delivery of small-molecule antitumor drugs in the pancreatic tumor microenvironment by reversing the accumulation of fibrotic stroma.